SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
SQZ Biotechnologies (NYSE: SQZ) announced a live R&D investor event on May 19, 2022, from 4:05 - 5:30 p.m. ET, focusing on its point-of-care manufacturing system and its SQZ® TAC clinical development program for celiac disease, with an FDA application expected in early 2023. Collaboration with STEMCELL Technologies will be part of the discussion, alongside a fireside chat featuring notable experts from MIT and the company leadership. The event will be accessible both onsite and virtually, with a replay available afterward.
- None.
- None.
The event will feature presentations on the company’s point-of-care (POC) manufacturing system, currently in internal testing, and its potential impact on cell therapy development. The company will also discuss its first anticipated clinical use in the SQZ® TAC clinical development program for celiac disease, which has an FDA investigational new drug application submission planned for the first half of 2023.
Company leadership will also discuss the collaboration with STEMCELL Technologies and the development of a research-use-only Cell Squeeze® system.
The event will include a special fireside chat on the present and future state of cell engineering. Speakers include:
-
Robert S. Langer , Sc.D.,Scientific Advisory Board Member and Founder ofSQZ Biotechnologies , and David H. Koch Institute Professor at theMassachusetts Institute of Technology -
Klavs F. Jensen , Ph.D., Board Member and Founder ofSQZ Biotechnologies , andWarren K. Lewis Professor of Chemical Engineering at theMassachusetts Institute of Technology -
Armon Sharei , Ph.D., Chief Executive Officer and Founder ofSQZ Biotechnologies -
Moderated by
Mike Huckman , Global Practice Leader,Executive Communications at Real Chemistry, and former CNBC Pharmaceuticals Reporter
Event Details
The company will host a live R&D Investor event with optional virtual participation on
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to events and presentations, our platform development, product candidates, preclinical and clinical activities, progress and outcomes, development plans, manufacturing capabilities, clinical safety and efficacy results, therapeutic potential, collaborations and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors and strategic collaborators; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and other filings with the
Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505006068/en/
Media
781-392-5514
john.lacey@sqzbiotech.com
Investors
857-760-0398
michael.kaiser@sqzbiotech.com
Source:
FAQ
What is the date and time of SQZ Biotechnologies' R&D investor event?
What topics will be discussed at SQZ Biotechnologies' investor event?
How can I participate in the SQZ Biotechnologies R&D investor event?
When is the FDA application submission planned for SQZ Biotechnologies' celiac disease treatment?